AMGN
AmgenAmgen is a biotechnology name in the health care sector. Over the past year it returned +39.3%, against +10.1% over three months and -9.3% over one. It trades 11.5% above its 200-day average, so the longer trend is confirming recent strength. Annualized volatility of 29.0% is moderate by single-stock standards.
Its worst peak-to-trough decline over the year was -16.6%, and it has traded a median $1.0B a day, the figure that decides whether a position can actually be entered and exited at posted prices. Its daily moves correlate 0.22 with the S&P 500 proxy, so it has been moving substantially on its own.
How AMGN scores on all four profiles
Its standing on steadiness, defensiveness and rebound, plus the factor-by-factor breakdown behind each score, and its closest and least-correlated peers among 7 others in Biotechnology.
Start a free 7-day trial| 1 day | -0.0% |
| 1 week | -3.6% |
| 1 month | -9.3% |
| 3 months | +10.1% |
| 6 months | +19.2% |
| 1 year | +39.3% |
| 12-1 momentum | +53.5% |
| Volatility (1y, annualized) | 29.0% |
| Max drawdown (1y) | -16.6% |
| Distance vs 200-day average | +11.5% |
| Return per unit of risk | 1.35 |
| Median daily dollar volume | $1.0B |
Get AMGN when it shows up in a ranking
Two editions a weekday, free, ranked lists built from this same data, on whatever the market is talking about.
Everything on this page is computed from daily adjusted closing prices. It contains no earnings, balance-sheet, guidance or ownership data, and it is not a valuation. Nothing here is tailored to your circumstances or a recommendation to buy or sell. Past performance does not predict future results.